Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$68.98

-0.18 (-0.26%)

13:03
10/21/19
10/21
13:03
10/21/19
13:03

BioMarin treatment of phenylketonuria granted FDA orphan status

BioMarin Pharmaceutical's adeno-associated virus vector encoding human phenylalanine hydroxylase was granted FDA orphan designation as a treatment of phenylketonuria, according to a post to the agency's website. Reference Link

  • 21

    Oct

  • 23

    Oct

  • 07

    Dec

BMRN BioMarin
$68.98

-0.18 (-0.26%)

09/13/19
PIPR
09/13/19
NO CHANGE
Target $120
PIPR
Overweight
Piper a buyer of BioMarin shares into next important data catalyst
Piper Jaffray analyst Christopher Raymond sees the vosoritide Phase 3 achondroplasia data, expected by early 2020, as the next important catalyst for shares of BioMarin Pharmaceutical. Assuming no surprises, vosoritide offers a "compelling" commercial premise, with "meaningful" upside to current expectations with little in the way of meaningful competition on the horizon, Raymond tells investors in a research note. The analyst is a buyer into the data and keeps an Overweight rating on BioMarin shares with a $120 price target.
10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
10/16/19
BOFA
10/16/19
INITIATION
Target $90
BOFA
Buy
BioMarin reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of BioMarin with a Buy rating and $90 price target, highlighting the base business's above average growth and a new product cycle on the way.
10/21/19
CANT
10/21/19
NO CHANGE
Target $129
CANT
Overweight
Cantor sees successful vosoritide Phase 3 trial for BioMarin by year end
Cantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on BioMarin with a $129 price target saying she has "high conviction" in a successful vosoritide Phase 3 trial by the end of 2019. This will be a key catalyst of focus for the shares, Merle tells investors in a research note. The analyst hosted Dr. Jonathan Day, the clinical lead for BioMarin's vosoritide program for achondroplasia, for a conference call on Friday and thinks Day sounded highly confident in Phase 3 success for vosoritide, "especially given powering assumptions." Merle thinks a successful Phase 3 will support further near-term revenue growth and profitability for BioMarin. On a successful Phase 3, the shares could trade up 10%-20% versus downside risk of ~20%, contends the analyst.

TODAY'S FREE FLY STORIES

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Hot Stocks
DXC Technology to pursue strategic alternatives for three businesses »

Says as part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Earnings
Fluent lowers FY19 revenue view to $87M-$88M from $93M-$98M »

Sees adjusted EBITDA is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

17:36
11/11/19
11/11
17:36
11/11/19
17:36
Earnings
Hudbay Minerals reports Q3 EPS ($1.05), consensus 18cc »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:34
11/11/19
11/11
17:34
11/11/19
17:34
Earnings
Fluent reports Q3 EPS (1c), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

MDGL

Madrigal Pharmaceuticals

$103.57

0.78 (0.76%)

17:34
11/11/19
11/11
17:34
11/11/19
17:34
Hot Stocks
Madrigal announces publication of 'positive' Phase 2 results for resmetirom »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KINS

Kingstone Companies

$8.72

-0.04 (-0.46%)

17:32
11/11/19
11/11
17:32
11/11/19
17:32
Earnings
Kingstone Companies reports Q3 EPS (23c), two estimates 28c »

Reports Q3 net written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

17:32
11/11/19
11/11
17:32
11/11/19
17:32
Earnings
Kemet sees Q3 revenue down 8%-13% sequentially, consensus $323.97M »

CEO, William Lowe Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

17:31
11/11/19
11/11
17:31
11/11/19
17:31
Earnings
Kemet reports Q2 adjusted EPS 66c, consensus 66c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NTZ

Natuzzi

$1.70

0.1 (6.25%)

17:21
11/11/19
11/11
17:21
11/11/19
17:21
Hot Stocks
Natuzzi Chief Commercial Officer Nazzario Pozzi departs »

Natuzzi announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:18
11/11/19
11/11
17:18
11/11/19
17:18
Earnings
Breaking Earnings news story on UGI Corporation »

UGI Corporation sees FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:17
11/11/19
11/11
17:17
11/11/19
17:17
Earnings
UGI Corporation reports Q4 EPS (27c), consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

, GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

17:05
11/11/19
11/11
17:05
11/11/19
17:05
Periodicals
State AGs gather in Colorado to go over Google antitrust probe, Reuters says »

State attorneys general…

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

FB

Facebook

$189.57

-1.29 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:03
11/11/19
11/11
17:03
11/11/19
17:03
Hot Stocks
Franco-Nevada reports 133,219 Gold Equivalent Ounces sold in Q3 »

"Franco-Nevada's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:02
11/11/19
11/11
17:02
11/11/19
17:02
Earnings
Franco-Nevada reports Q3 EPS 54c, may not compare to consensus 27c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ENR

Energizer

$43.11

-0.265 (-0.61%)

16:55
11/11/19
11/11
16:55
11/11/19
16:55
Hot Stocks
Energizer appoints new CFO, Chief Legal Officer, and Chief Accounting Officer »

Energizer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

16:52
11/11/19
11/11
16:52
11/11/19
16:52
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$78.70

0.22 (0.28%)

, BREW

Craft Brew

$7.33

0.06 (0.83%)

16:51
11/11/19
11/11
16:51
11/11/19
16:51
Hot Stocks
Anheuser-Busch to buy remaining Craft Brew Alliance stake for $16.50 per share »

Today, Craft Brew…

BUD

AB InBev

$78.70

0.22 (0.28%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 27

    Feb

CHAP

Chaparral Energy

$0.90

0.089 (10.99%)

16:47
11/11/19
11/11
16:47
11/11/19
16:47
Earnings
Chaparral Energy reports Q3 EPS ($2.86), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:43
11/11/19
11/11
16:43
11/11/19
16:43
Hot Stocks
DXC Technology says will pursue strategic alternatives for adjacent business »

In Q2 presentation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:41
11/11/19
11/11
16:41
11/11/19
16:41
Earnings
DXC Technology cuts FY20 EPS view to $5.25-$5.75 from $7.00-$7.75 »

Consensus $7.17. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:35
11/11/19
11/11
16:35
11/11/19
16:35
Hot Stocks
Lonestar sees Q4 production 17,200-17,600 BOE/d »

Lonestar has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NFE

New Fortress Energy

$15.86

-0.88 (-5.26%)

16:34
11/11/19
11/11
16:34
11/11/19
16:34
Earnings
New Fortress Energy reports Q3 EPS (30c), consensus (16c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.